Fri, May 9, 6:31 PM (38 days ago)
**Anika Therapeutics, Inc. (ANIK) Q1 2025 Financial Summary** **Financial Health & Performance:** - **Revenue:** $26.2 million, down 10% YoY due to lower OEM channel sales and discontinued non-orthopedic products. - **Gross Profit:** $14.7 million, down 23% YoY, with a gross margin of 56% (down from 65%). - **Operating Expenses:** $18.97 million, down 12% YoY, with R&D and SG&A expenses decreasing by 5% and 14%, respectively. - **Net Loss:** $4.87 million, up 8% YoY, with a loss from continuing operations of $3.96 million. - **Cash Flow:** Negative operating cash flow of $0.13 million, with investing and financing activities providing $1.67 million and using $5.44 million, respectively. - **Cash Position:** $53.4 million in cash and cash equivalents, down from $55.6 million in Q4 2024. **Key Metrics & Trends:** - **Revenue Mix:** OEM channel down 23%, commercial channel up 18%. - **Profit Margins:** Decreased gross margin due to higher manufacturing costs and lower average selling prices. - **Earnings Changes:** Increased loss from continuing operations due to lower revenue and higher manufacturing costs. - **Future Operations Impact:** Strategic shift to focus on OA Pain Management and Regenerative Solutions, with divestitures of Arthrosurface and Parcus Medical. **Uncertainties & Risks:** - **Market Risks:** Dependence on key customers, regulatory approvals, and competition. - **Operational Risks:** Supply chain disruptions, manufacturing issues, and integration of acquired businesses. - **Financial Risks:** Cash flow management, debt levels, and access to capital. **Strategic Focus:** - **Product Portfolio:** Expanding HA-based products, introducing new products like Cingal and Hyalofast in the US. - **Commercial Strategy:** Leveraging global expertise, pursuing strategic inorganic growth, and expanding international presence. - **Financial Strategy:** Managing cash flow, optimizing capital structure, and maintaining financial flexibility. **Ticker:** ANIK **Note:** Amounts are in thousands, except per share data. This summary is based on the provided Q1 2025 financial data and does not include forward-looking statements or future projections.